Physician-scientists at Memorial Sloan Kettering Cancer Center (MSK) recently published two papers that advance the science ...

Renier Brentjens, a CAR T-cell pioneer, views armored CAR T-cells as a promising avenue for treating solid tumors and ...

If preclinical findings were translated into the clinic, they could shorten the CAR-T generation lead time from two weeks to ...

It’s more common in older adults, people with weakened immune systems, and people with primary CNS lymphoma. There are two main types of lymphocytes, called B cells and T cells. But the kind ...

Researchers with City of Hope and MSK have created a tool that uses machine learning to assess a non-Hodgkin lymphoma (NHL) ...

FDA grants fast track designation to azer-cel, an allogeneic CAR T-cell therapy, for relapsed or refractory diffuse large ...

For many decades, the foundations of cancer treatment have been surgery, chemotherapy, and radiation therapy. But, in recent years, a newer therapy in the form of immunotherapy has emerged, ...

Frederick L. Locke, MD, discussed cema-cel's safety, efficacy, and potential for treating large B-cell lymphoma in earlier ...

Researchers Uncover Mechanism That Fuels Growth of Aggressive B-Cell Lymphoma June 18 ... Details About Rare Second Cancers Related to CAR-T Therapy June 12, 2024 — A new detailed analysis ...

Data incorporated for this study were collected from 9 centers in the UK focused on third-line and beyond chimeric antigen ...

The company said that ZAMTO Cell is designed to target both CD19 and CD20, which could improve treatment efficacy.